VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRLA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRLAIRulya Therapeutics Inc.
$40.59$39M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIRLACash Flow

IRulya Therapeutics Inc. (IRLA) Cash Flow Statement

9Y historyFree accessUpdated daily

Operational liquidity is under severe pressure, evidenced by a $7.6 million negative operating cash flow in 2026Q1 that highlights the company's inability to self-fund its R&D expenses.

Income StatementBalance SheetCash FlowRatios

IRLA Cash Flow Statement

Annual statement

IRLA Cash Flow Statement

IRulya Therapeutics Inc. (IRLA) cash flow statement — 9-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Cash from Operations-46.84M-41.42M-31.9M-18.29M-44.04M-62.93M-50.82M-33.28M-11.7M-9.83M
Operating CF Margin %----------
Operating CF Growth %-82.8%-29.84%-74.41%58.46%30.02%-23.84%-52.71%-184.54%-19.01%-
Net Income-106.78M-83.98M-56.83M-31.39M-51.66M-89.94M-76.85M-36.98M-12.48M-12.23M
Depreciation & Amortization131K142K186K322K204K344K332K188K51K45K
Stock-Based Compensation16.21M5.11M4.75M5.22M16.62M29.85M14.47M2.06M155K38K
Deferred Taxes0-4.96M0-248K-284K878K635K-812K-145K222K
Other Non-Cash Items48.92M29.43M20.48M5.82M913K199K367K367K1.11M1.64M
Working Capital Changes-5.31M12.84M-484K1.98M-9.83M-4.26M10.23M1.9M-390K460K
Change in Receivables0000000000
Change in Inventory0000000000
Change in Payables2M-940K927K-288K-5.94M1.36M480K2.58M-23K223K
Cash from Investing-39.72M23.23M21.91M-5.76M18M58.95M-52.43M-17.75M-46.75M-77K
Capital Expenditures-75K-352K-257K-160K-133K-180K-52K-55K-212K-77K
CapEx % of Revenue----------
Acquisitions5.2M00-2.12M10.59M-58.95M52.43M-812K00
Investments----------
Other Investing542K1.01M2.35M-910K70K58.95M-52.43M812K-46.54M0
Cash from Financing120.4M17.91M-4.78M143K707K6.81M118.88M77.37M75.93M7.75M
Debt Issued (Net)-5.54M00-6K-49K0-34K-559K250K7.75M
Equity Issued (Net)126.01M17.91M225K149K608K6.81M117.63M77.83M75.69M0
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing-66K0-5M0148K01.28M98K-10K0
Net Change in Cash33.37M-403K-14.54M-23.83M-25.14M2.88M15.63M26.34M17.48M-2.15M
Free Cash Flow-46.91M-41.78M-32.16M-18.45M-44.17M-63.11M-50.87M-33.33M-11.91M-9.9M
FCF Margin %----------
FCF Growth %-20.35%-29.9%-74.3%58.23%30.01%-24.07%-52.62%-179.94%-20.22%-
FCF per Share-3.91-166.78-148.68-99.11-263.73-424.73-348.71-350.27-110.50-91.91
FCF Conversion (FCF/Net Income)0.44x0.49x0.56x0.58x0.85x0.70x0.66x0.90x0.94x0.80x
Interest Paid0000000000
Taxes Paid000000001K1K

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Disconnect Masks Cash Burn

According to recent financial filings, QNCX reported a net income of $35.9 million in 2026Q1, yet the company simultaneously generated negative operating cash flow of $7.6 million, highlighting a significant divergence between accounting profit and the actual cash resources available to support ongoing clinical operations.

The reported net income appears to be driven by non-operating accounting adjustments that provide no tangible benefit to the company's liquidity position. Investors should interpret this disconnect as a warning that the firm's reported profitability is not indicative of its ability to self-fund its research and development pipeline.

Persistent Negative Free Cash Flow

As reported in historical cash flow statements, QNCX has consistently recorded negative free cash flow, with quarterly outflows ranging between $6.1 million and $11.5 million, underscoring the company's total dependence on external financing to sustain its clinical-stage development programs and administrative overhead.

The lack of positive free cash flow is a structural reality for a pre-revenue biotech firm, but the consistency of these outflows suggests that the company has yet to reach a meaningful inflection point in its clinical development. The absence of any positive FCF margin indicates that the business model remains entirely reliant on capital markets for survival.

Volatile Working Capital Obscures Burn

Based on quarterly data, QNCX exhibits significant volatility in working capital changes, including a $14.4 million outflow in 2026Q1, which suggests that timing differences in vendor payments and clinical trial accruals are creating substantial, unpredictable swings in the company's quarterly cash consumption profile.

These fluctuations in working capital make it difficult to discern the underlying steady-state burn rate of the business. Analysts should monitor these shifts closely, as they may mask the true cost of clinical trial execution and the potential for future liquidity crunches.

SBC and Non-Cash Distortions

Data from recent filings indicates that stock-based compensation consistently adds over $1 million per quarter to the company's expenses, which, while non-cash, serves to dilute existing shareholders without providing the immediate cash liquidity required to fund the company's intensive clinical research and development activities.

The reliance on equity-based incentives suggests that management is attempting to preserve cash, yet this strategy does not address the fundamental need for capital to advance the NOV004 program. Investors should view these non-cash adjustments as a secondary cost that, while not impacting the immediate cash balance, significantly alters the long-term value proposition for equity holders.

IRLA — Frequently Asked Questions

Quick answers to the most common questions about buying IRLA stock.

How much cash does IRulya Therapeutics Inc. (IRLA) generate from operations?

IRulya Therapeutics Inc. (IRLA) generated $-41.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is IRulya Therapeutics Inc.'s free cash flow?

IRulya Therapeutics Inc. (IRLA) reported negative free cash flow of $41.8M in 2025, indicating capital requirements exceeded cash from operations.

What is IRulya Therapeutics Inc.'s capital expenditure (CapEx)?

IRulya Therapeutics Inc. (IRLA) spent $0.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.